Document is current

Article History

Received: 29 July 2022

Revised: 30 August 2022

Accepted: 21 September 2022

First Online: 26 September 2022

Declarations

:

: Dr. Tamai received honoraria from AbbVie and Eisai. Dr. Kikuchi received honoraria from Bristol Myers Squibb, Chugai and Mitsubishi-Tanabe. Dr. Izumi received honoraria from AbbVie, Asahi-Kasei, Ayumi, Bristol Myers Squibb, Chugai, Eisai and Eli Lilly. Dr. Otomo received honoraria from AbbVie, Asahi Kasei, Astellas, Bristol-Myers Squibb, Chugai, Eli Lilly, Glaxo SmithKline, Jansen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi and UCB. Dr. Yamaoka received honoraria from Pfizer, Chugai Pharma, Takeda Industrial Pharma, Astellas Pharma, Abbvie, Bristol-Myers Squibb, Mitsubishi-Tanabe Pharma, GlaxoSmithkline, Eli Lilly, Janssen Pharma, Eisai Pharma, Actelion Pharmaceuticals Japan, Asahikasei Pharma Corp, Ono Pharma, Otsuka Pharma, Nippon Shinyaku, Gilead G.K, Daiichi Sankyo, Boehringer Ingelheim Japan, Japan Tobacco Inc., Hisamitsu Pharma Co, MSD, Sanofi, AYUMI Pharma Co, and Nippon Kayaku. Dr. Takeuchi received honoraria from Astellas, AbbVie, Ayumi, Bristol Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Glaxo Smith Kline, Janssen, Mitsubishi-Tanabe, Nippon-kayaku, Novartis, Pfizer, Sanofi, UCB and research support from Asahi Kasei, AbbVie, Ayumi, Boehringer-Ingelheim, Chugai, Eisai, Eli Lilly, Mitsubishi-Tanabe, Sanofi, and UCB. Dr. Kaneko received honoraria from Asahi Kasei, Astellas, Ayumi, Bristol Myers Squibb, Chugai, Eisai, Elli Lilly, Mitsubishi-Tanabe, Novartis, UCB, and research support from AbbVie, Chugai, Eisai, Mitsubishi-Tanabe, and UCB. The other authors declare no relevant conflicts of interest.